BNGO · Bionano Genomics filed Amendment No

Bionano Genomics filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $400 million in securities (common stock, preferred stock, debt securities, warrants, units). The filing replaces a prior shelf that expires November 6, 2026 and carries forward $148.1 million of unsold securities from that prior shelf. The company's public float is $25.6 million, and due to its small float, it is limited under General Instruction I.B.6 to selling no more than one-third of that float ($8.5 million) in any 12-month period in primary offerings. The filing signals potential future dilution, but the actual amount sellable is tightly constrained by the float limitation.

• Shelf registration of up to $400,000,000 in securities (common, preferred, debt, warrants, units).
• Public float is $25,582,638.72 based on 13,979,584 non-affiliate shares at a $1.83 reference price.
• Under General Instruction I.B.6, the company cannot sell more than one-third of its public float ($8.5 million) in primary offerings in any 12-month period while float stays below $75 million.
• The filing carries forward $148,146,961.18 of unsold securities from the prior S-3 (File No. 333-270459).